中文
| Catalogue |
| Recommend Products |
Company News
- OGT Delivers Superior MRD Detection Capabilities with New SureSeq Myeloid MRD Panel 2/7/2025
- OGT Unveils the Enhanced SureSeq CLL + CNV V3 Panel for Deeper Insights into CLL Progressi... 12/3/2024
- OGT Expands NGS Operations to State-of-the-art Facility in Oxford Technology Park 2/17/2024
- OGT and Intelliseq Launch NGS Reporting and Interpretation for All Myeloid Malignancy Pane... 10/27/2023
- OGT and Intelliseq Forge Partnership to Advance Clinical and Biological Insight from NGS D... 10/16/2023
- OGT Announces Commercial Partnership with Applied Spectral Imaging 6/28/2023
- OGT First to Achieve IVDR-certification for Fish Probes 3/15/2023
- OGT Launches SureSeq Myeloid Plus Panel and Universal NGS Complete Workflow 10/6/2022
- OGT Welcomes Adrian Smith as CEO 4/6/2022
- OGT Expands Latest Support and Training Initiative with CytoCell University 8/5/2021
- OGT Pledges Partnership with Significant Brand Refresh and Integration 3/25/2021
- OGT’s NGS Panels to be Featured in User Workshop at AMP 2020 11/10/2020
- OGT Expands NGS Cancer Panel Offering 11/4/2020
- NHS Study Confirms OGT’s CytoSure Constitutional v3 Array has Significantly Higher Reporti... 7/23/2020
- OGT’s Cytocell Portfolio to Become Available Via Sysmex in China and Spain 7/8/2020
- OGT Delivers Translocation and Partial Tandem Duplication Detection with Updates to SureSe... 4/8/2020
- OGT Launches Breakthrough CytoSure NGS Panel for Constitutional Cytogenetics 1/30/2020
- OGT Unveils Reliable Somatic CNV Detection for CLL with New NGS Panel 1/15/2020
- OGT Develops Transformative Constitutional NGS Panel 12/11/2019
- OGT Continues Move into Molecular Diagnostics Markets with MDSAP Certification 11/20/2019